Search results for "GiST"

showing 10 items of 3463 documents

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, mu…

2013

Contains fulltext : 118365.pdf (Publisher’s version ) (Closed access) BACKGROUND: Until now, only imatinib and sunitinib have proven clinical benefit in patients with gastrointestinal stromal tumours (GIST), but almost all metastatic GIST eventually develop resistance to these agents, resulting in fatal disease progression. We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib. METHODS: We did this phase 3 trial at 57 hospitals in 17 countries. Patients with histologically confirmed, metastatic or unresectable GIST, with failure of at least previous imatinib and sunitinib were rando…

OncologyMaleIndolesPyridinesSettore MED/06 - Oncologia MedicaSU11248MedizinPiperazineslaw.inventionchemistry.chemical_compoundRandomized controlled triallawClinical endpointSunitinibTreatment Failureregorafenib; gastrointestinal stromal tumours; imatinib and sunitinibGastrointestinal Neoplasmseducation.field_of_studyGiSTSunitinibKITAge-related aspects of cancer Quality of hospital and integrated care [ONCOL 2]General MedicineMiddle AgedSurvival RateBenzamidesImatinib MesylateFemaleADJUVANT IMATINIBTYROSINE KINASE INHIBITORColorectal NeoplasmsLife Sciences & Biomedicinemedicine.drugGROWTH-FACTORmedicine.medical_specialtyGastrointestinal Stromal TumorsPopulationMESYLATEAntineoplastic AgentsIMATINIBArticleMECHANISMSMedicine General & InternalDouble-Blind MethodTranslational research [ONCOL 3]General & Internal MedicineRegorafenibInternal medicineMANAGEMENTmedicineHumansPyrroleseducationProtein Kinase InhibitorsAgedScience & TechnologyGASTROINTESTINAL STROMAL TUMOURSimatinib and sunitinibMUTATIONSbusiness.industryPhenylurea CompoundsGIST regorafenib imatinib sunitinib phase III trialSurgeryClinical trialImatinib mesylatePyrimidineschemistryregorafenibbusinessRESISTANCE
researchProduct

Circulating leukocyte telomere length and oxidative stress: A new target for statin therapy

2011

International audience; Objectives: We investigated the relationship between prior statin therapy and leukocyte telomere length (LTL), as well as their interaction with potential new biomarkers of oxidative deoxyribonucleic acid (DNA) lesions and reactive oxygen species-induced inflammation.Methods and results: From patients admitted for an acute myocardial infarction, LTL was assessed by quantitative polymerase chain reaction (Q-PCR), and leukocyte Finkel-Biskis-Jinkins osteosarcoma (FOS) and 8-oxoguanine DNA glycosylase (OGG1) messenger ribonucleic acid (mRNA) levels were measured by retrotranscription Q-PCR. Patients under prior chronic statin therapy were compared with patients without …

OncologyMaleMyocardial Infarction030204 cardiovascular system & hematologymedicine.disease_causeDNA Glycosylases0302 clinical medicineRisk FactorsLeukocytesMyocardial infarctionComputingMilieux_MISCELLANEOUSAged 80 and over0303 health sciencesReverse Transcriptase Polymerase Chain ReactionConfoundingMiddle AgedTelomere3. Good health[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemReal-time polymerase chain reactionOsteosarcomaFemalemedicine.symptomCardiology and Cardiovascular MedicineProto-Oncogene Proteins c-fosGenetic Markersmedicine.medical_specialtyStatinmedicine.drug_classInflammationReal-Time Polymerase Chain ReactionRisk Assessment03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansRNA MessengerPropensity Score030304 developmental biologyAgedDyslipidemiasChi-Square Distributionbusiness.industrystatinoxidative stress 2medicine.diseaseLeukocyte telomere lengthSurgeryOxidative StressLogistic ModelsinflammationLinear ModelsHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessChi-squared distributionOxidative stress
researchProduct

Prediction of Non-sentinel Node Status in Patients with Melanoma and Positive Sentinel Node Biopsy: An Italian Melanoma Intergroup (IMI) Study

2018

Background and Purpose: Approximately 20% of melanoma patients harbor metastases in non-sentinel nodes (NSNs) after a positive sentinel node biopsy (SNB), and recent evidence questions the therapeutic benefit of completion lymph node dissection (CLND). We built a nomogram for prediction of NSN status in melanoma patients with positive SNB. Methods: Data on anthropometric and clinicopathological features of patients with cutaneous melanoma who underwent CLND after a positive SNB were collected from nine Italian centers. Multivariate logistic regression was utilized to identify predictors of NSN status in a training set, while model efficiency was validated in a validation set. Results: Data …

OncologyMaleSkin NeoplasmsSettore MED/19 - Chirurgia PlasticaLogistic regressionSurgery; Oncology; Sentinel Node Biopsy; Melanoma0302 clinical medicineRisk FactorsMedicine030212 general & internal medicineLymph nodeMelanomaSurgery Oncology lymphnodes melanoma metastasis dissection biomarkerslymphnodesMelanomaTorsoSentinel nodeMiddle AgedTumor Burdenmedicine.anatomical_structuredissectionItalyOncologyHead and Neck Neoplasms030220 oncology & carcinogenesisArea Under CurveLymphatic MetastasisSurgery; OncologyFemalemedicine.medical_specialtyNO03 medical and health sciencesSentinel Node BiopsyInternal medicinemetastasisHumansAgedRetrospective StudiesReceiver operating characteristicbusiness.industrySentinel Lymph Node BiopsybiomarkersExtremitiesNomogrammedicine.diseaseConfidence intervalNomogramsROC CurveCutaneous melanomaLymph Node ExcisionSurgeryLymph Nodesbusiness
researchProduct

Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective …

2017

Abstract Introduction:Even in the era of novel targeted therapies for the treatment of Chronic Lymphocytic Leukemia (CLL) patients, such as BTK, PI3K and BCL2 inhibitors, allogeneic hematopoietic stem cell transplantations (alloHCT) will remain an important treatment option for a subset of patients with very high risk CLL. The current study focused on the impact of center and procedure-related factors on outcomes after alloHCT, taking into account the impact of patient- and disease-related risk factors. Patients and Methods:Data of 684 CLL patients who received a first alloHCT between 2000 and 2011 were analyzed. Their data were collected as part of the EBMT CLL Data Quality Initiative. Out…

OncologyMaleTransplantation ConditioningCancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]Chronic lymphocytic leukemiaMedizinQUALITY MANAGEMENT-SYSTEMKaplan-Meier Estimaterisk factor analysisGUIDELINESBiochemistryallogeneic stem cell transplantation; centre effects; chronic lymphocytic leukaemia; frailties; risk factor analysiscentre effectsTransplantation Conditioning / methods0302 clinical medicineRecurrenceRisk Factorsallogeneic stem cell transplantationLeukemia Lymphocytic Chronic B-Cell / mortalityRegistriesDelivery of Health Care / statistics & numerical dataIBRUTINIBddc:6160303 health sciencesALEMTUZUMABHazard ratioHematopoietic Stem Cell TransplantationProfessional PracticeHematologyMiddle Aged3. Good healthEurope030220 oncology & carcinogenesisABT-199CohortSURVIVALAlemtuzumabFemaleEurope / epidemiologymedicine.drugAdultmedicine.medical_specialtyAllogeneic transplantationImmunologyLower riskDIAGNOSISSettore MED/01 - Statistica Medica03 medical and health sciencesLeukemia Lymphocytic Chronic B-Cell / therapyHematopoietic Stem Cell Transplantation / methodsInternal medicinemedicineHumansKarnofsky Performance Status030304 developmental biologyAgedRetrospective Studiesbusiness.industryProportional hazards modelCHRONIC LYMPHOCYTIC-LEUKEMIARetrospective cohort studySTEM-CELL TRANSPLANTATIONCell Biologymedicine.diseaseLeukemia Lymphocytic Chronic B-CellConfidence intervalSurgeryProfessional Practice / statistics & numerical dataTransplantationbusinessDelivery of Health Carefrailtieschronic lymphocytic leukaemia030215 immunologyRESPONSES
researchProduct

Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer

2016

International audience; Background: To determine whether dose/volume specific endpoints (DVSE) or Area under the rectal DVH curve (rAUC) better predict acute gastrointestinal (GI) toxicity in prostate cancer patients treated with IMRT in the era of daily image guidance (IG-IMRT). Methods: A set of DVSE was recorded from V25 to V75 (increments of 5Gy) (both in % and in cc) for 180 men. The rAUC was calculated for doses ranging between 25Gy and 50Gy (rAUC(25-50)). Univariate and multivariate logistic regressions were performed to determine the relationship between DVSE or rAUC(25-50) and the appearance of any acute GI toxicity. Results: The rates of acute grade 1 (G1), G2 and G3 GI toxicities…

OncologyMale[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentGastroenterology030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineProstate cancer0302 clinical medicineProstateLarge intestineConformal Radiation-Therapy[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingAged 80 and overGastrointestinal tractProstate cancerRadiotherapy DosageMiddle Aged3. Good healthmedicine.anatomical_structureImpactOncologyRadiology Nuclear Medicine and imaging030220 oncology & carcinogenesisArea Under CurveToxicityImage Guidancemedicine.medical_specialtyRectum[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciencesInternal medicinemedicineBiochemical ControlHumansRadiology Nuclear Medicine and imagingRadiation InjuriesAgedRadiotherapybusiness.industryResearchRectumProstatic Neoplasmsmedicine.diseaseRadiation therapyAcute rectal toxicity predictive factorLogistic ModelsRadiotherapy Intensity-ModulatedbusinessAbsolute volumeRadiation Oncology (London, England)
researchProduct

Patterns of Prior and Subsequent Neoplasms in Children and Adolescents With Soft Tissue Sarcomas.

2020

Background The occurrence of prior, concurrent and subsequent neoplasms (SN) represents a serious problem in children and adolescents with soft tissue sarcomas. Pathogenic germline variants contribute to the diagnosis of multiple neoplasms in sarcoma survivors. Materials and methods The records of 748 children and adolescents, diagnosed with soft tissue sarcomas and registered in trials/registries by the cooperative soft tissue sarcoma (Cooperative Weichteilsarkom Studie) group, were reviewed for the occurrence of SNs. Reference histology review was available for all cases; the presence of oncogenic fusions known at the time of diagnosis was confirmed for fusion-positive (F+) entities. Resu…

OncologyMalemedicine.medical_specialtyAdolescentOncogene Proteins FusionGermline03 medical and health sciences0302 clinical medicineCancer SurvivorsRisk FactorsInternal medicineGermanyBiomarkers TumorMedicineHumansRegistriesNeurofibromatosisChildGerm-Line MutationClinical Trials as Topicbusiness.industryIncidence (epidemiology)Soft tissue sarcomaIncidenceSoft tissueInfantHistologyNeoplasms Second PrimarySarcomaHematologymedicine.diseasePrognosisCombined Modality TherapySurvival RateOncology030220 oncology & carcinogenesisChild PreschoolPediatrics Perinatology and Child HealthFemaleSarcomabusiness030215 immunologyFollow-Up StudiesJournal of pediatric hematology/oncology
researchProduct

Epidemiology and prognosis of synchronous and metachronous colon cancer metastases: a French population-based study.

2014

Epidemiological data on synchronous and metachronous metastatic colon cancer are scarce. We assessed epidemiological characteristics and survival in synchronous and metachronous metastatic colon cancer in a French population.Our study included 932 cases of metastatic colon cancer diagnosed in 1999-2010 and registered in a population-based cancer registry; 758 were synchronous colon metastases and 174 metachronous metastases from resected primary colon cancers diagnosed in 1999-2005. Univariate relative survival was calculated and a multivariate model with proportional hazard applied to net survival by interval was used.Mean age at diagnosis was 71.1 years for patients with metachronous meta…

OncologyMalemedicine.medical_specialtyColorectal cancermedicine.medical_treatmentPopulationNeoplasms Multiple PrimaryMetachronous metastasisRisk FactorsInternal medicineEpidemiologyMedicineHumanseducationAgedRetrospective StudiesChemotherapyeducation.field_of_studyHepatologyRelative survivalbusiness.industryGastroenterologyNeoplasms Second PrimaryOdds ratiomedicine.diseasePrognosisCancer registrySurvival RatePopulation SurveillanceColonic NeoplasmsFemaleFranceMorbiditybusinessFollow-Up StudiesDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Immunomodulatory Therapy Does Not Increase the Risk of Cancer in Persons With Inflammatory Bowel Disease and a History of Extracolonic Cancers.

2019

Immunosuppressant therapies (IMTs; thiopurines, anti-tumor necrosis factor agents) may influence the immunologic control of cancer and might facilitate the spread and recurrence of cancer. This study assesses the impact of the use of IMTs on the development of incident cancers (recurrent or new) in patients with inflammatory bowel disease (IBD) and a history of malignancy.Patients with IBD included in the ENEIDA registry with a history of cancer without being exposed to IMTs were identified and retrospectively reviewed and compared regarding further treatment with IMTs or not by means of a log-rank test.Overall, 520 patients with previous extracolonic cancer naive to IMTs before the diagnos…

OncologyMalemedicine.medical_specialtyInflammatory bowel diseaseRisk AssessmentTime-to-TreatmentImmunomodulation03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineNeoplasmsmedicineHumanscardiovascular diseasesRegistriesHepatologybusiness.industryIncidence (epidemiology)IncidenceGastroenterologyCancerMiddle Agedmedicine.diseaseInflammatory Bowel DiseasesOutcome and Process Assessment Health CareSpain030220 oncology & carcinogenesiscardiovascular system030211 gastroenterology & hepatologyFemaleRisk assessmentbusinessImmunosuppressive AgentsThe American journal of gastroenterology
researchProduct

Childhood cancer incidence and survival in Spain

2010

Abstract Background: This article affords an overview of the patterns and time trends of childhood cancer incidence (1983–2002) and survival (1991–2002) in Spain. Patients and methods: A population-based study was conducted, including 5936 cases for incidence and 3257 for survival analyses. Differences in incidence were tested with the standardised incidence ratio. Trends were analysed for all tumours, and for all malignant, haematological, central nervous system (CNS) (all and only malignant) and other solid tumours. Incidence trends were analysed using Poisson and Bayesian joinpoint models. Observed, relative and age-adjusted survival rates were calculated, and trends were tested using th…

OncologyMaletrendsmedicine.medical_specialtyPathologyAdolescentPopulationChildhood cancersurvivalInternal medicineNeoplasmsEpidemiologymedicineHumanschildhood cancerRegistrieseducationChildSurvival rateeducation.field_of_studybusiness.industryIncidence (epidemiology)IncidenceAge FactorsInfant NewbornInfantHematologymedicine.diseaseLymphomaLog-rank testSurvival RateLeukemiaOncologycancer registriesSpainChild PreschoolincidenceFemalebusiness
researchProduct

Incidence, survival and prevalence of myeloid malignancies in Europe.

2012

Abstract Background The Surveillance of Rare Cancers in Europe (RARECARE) project aims at increasing knowledge of rare cancers in Europe. This manuscript describes the epidemiology of myeloid malignancies (MMs), taking into account the morphological characterisation of these tumours. Methods We used data gathered by RARECARE on cancer patients diagnosed from 1995 to 2002 and archived in 64 European population-based cancer registries, followed up to 31st December 2003 or later. Results The overall annual crude incidence of MMs was 8.6 per 100,000. Acute myeloid leukaemia (AML) and myeloproliferative neoplasms (MPN) were most common, with incidence rates of 3.7 and 3.1 per 100,000 year respec…

OncologyMyeloidMaleCancer ResearchMyeloidSurvivalChronic myelomonocytic leukaemiaCancer registry Incidence Prevalence Survival Myeloid malignancies Acute myeloid leukaemia Myelodysplastic syndrome Chronic myeloid leukaemia Chronic myelomonocytic leukaemiaImmunophenotypingEpidemiologyPrevalenceChildLeukemiaIncidence (epidemiology)IncidenceMyeloid malignanciesCancer registryMiddle AgedEuropeLeukemia Myeloid AcuteLeukemiamedicine.anatomical_structureOncologyChild PreschoolMyelodysplastic-Myeloproliferative Diseases/epidemiology/mortalityMyelodysplastic Syndromes/epidemiology/mortalityFemaleAdultmedicine.medical_specialtyAdolescentAcute myeloid leukaemiaNOEurope/epidemiologyInternal medicinemedicinecancer Incidence; survival and prevalence; myeloid malignanciesHumansPreschoolChronic myeloid leukaemiaddc:613AgedMyeloproliferative Disorders/epidemiology/mortalityMyeloproliferative Disordersbusiness.industryMyelodysplastic syndromesInfant NewbornCancerInfantcancer Incidencemedicine.diseaseNewbornMyelodysplastic-Myeloproliferative DiseasesCancer registrysurvival and prevalenceMyelodysplastic SyndromesImmunologyAcute/epidemiology/mortalitybusinessMyelodysplastic syndrome
researchProduct